As part of FDA’s proposed biosimilar naming convention, most biologics and biosimilars will have a suffix added to their product’s nonproprietary name that each sponsor must request.
The Rules Of The Biosimilar Suffix
FDA guidance outlines dos and don’ts for proposing a nonproprietary name suffix for a biosimilar.